^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gresonitamab (AMG 910)

    i
    Other names: AMG 910
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Terminated, Amgen | Completed --> Terminated; Business Decision
    Trial termination
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    gresonitamab (AMG 910)
    over1year
    CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. (PubMed, Gastroenterology)
    Our data suggest that BiTE molecule treatment converts Treg function from immunosuppressive to immune enhancing, leading to antitumor activity in immunogenically "cold" tumors.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 overexpression
    |
    gresonitamab (AMG 910)
    over2years
    Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1, N=16, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Jun 2022 | Trial primary completion date: Nov 2023 --> Jun 2022
    Trial completion • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    gresonitamab (AMG 910)
    almost3years
    Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Amgen | N=70 --> 16 | Trial completion date: Oct 2025 --> Nov 2023 | Trial primary completion date: Oct 2025 --> Nov 2023 | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    gresonitamab (AMG 910)
    3years
    Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1, N=70, Recruiting, Amgen | Trial completion date: Jan 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025
    Clinical • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    gresonitamab (AMG 910)